Montag A & Associates Inc. Makes New Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC

Montag A & Associates Inc. purchased a new position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the second quarter, HoldingsChannel reports. The fund purchased 750 shares of the company’s stock, valued at approximately $182,000.

Several other institutional investors and hedge funds have also modified their holdings of ONC. Caitong International Asset Management Co. Ltd acquired a new stake in BeOne Medicines during the second quarter worth approximately $28,000. Farther Finance Advisors LLC acquired a new position in BeOne Medicines in the 2nd quarter valued at $39,000. Signaturefd LLC acquired a new stake in shares of BeOne Medicines during the second quarter worth $49,000. Parallel Advisors LLC purchased a new stake in shares of BeOne Medicines in the second quarter valued at $59,000. Finally, FNY Investment Advisers LLC acquired a new position in BeOne Medicines in the second quarter valued at $121,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $377.47 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $170.99 and a 1-year high of $379.33. The firm has a market capitalization of $41.39 billion, a P/E ratio of 740.14 and a beta of 0.31. The business’s 50-day simple moving average is $328.43 and its 200-day simple moving average is $290.11.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 27,803 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total transaction of $9,055,715.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lai Wang sold 5,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total transaction of $1,750,300.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 56,267 shares of company stock valued at $18,740,356 in the last three months. 6.62% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays began coverage on BeOne Medicines in a research note on Thursday, September 18th. They issued an “overweight” rating and a $385.00 price target on the stock. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, October 8th. Guggenheim upped their price target on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Finally, Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $357.33.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.